Biotech Co.* |
Pharma Co. |
Product | Terms/Details (Date) |
Ambrx Inc.* |
CMC Biopharmaceuticals A/S (Denmark) |
Deal for the manufacture of an Ambrx pegylated recom- binant growth hormone |
CMC will manufacture the product for use in human clinical studies; terms of the deal were not disclosed (6/3) |
Antisoma plc |
Heraeus GmbH (Germany) |
Heraeus will provide supplies of Antisoma's AS1410 for clinical trials |
Trials of the telomere-targeting agent are expected to begin in 2006; terms of the deal were not disclosed (6/2) |
BioSante |
Undisclosed U.S.-based company |
Deal for the manufacture of large-scale quantities of BioSante's calcium phosphate-based nanotechnology |
The product will be tested by another company to develop an oral formulation of a marketed injectable protein product; terms were not disclosed (5/3) |
Cellectricon |
Dipsi Industrie (France) |
Dipsi will distribute the Dynaflow System for ion channel drug discovery in France |
Dipsi will provide sales and technical support to the French market under undisclosed terms (5/17) |
Codexis Inc.* |
Shasun Chemicals and Drugs Ltd. (India) |
Manufacturing and supply agreement for a pharmaceutical intermediate for a generic drug |
Shasun will manufacture the compound and Codexis will market it worldwide to the generic industry; Codexis will provide the biocatalyst for use in production, and they will share profits on sales (5/11) |
Combimatrix |
Inter Medical Co. Ltd. (Japan) |
Inter Medical will distribute CombiMatrix's CustomArray microarray products in Japan |
Terms of the nonexclusive distribution deal were not disclosed (5/2) |
Corautus |
Boehringer Ingelheim Austria GmbH |
Deal covering manufacturing of VEGF-2 plasmid DNA for Phase III trials and future commercial use |
BI will manufacture Corautus' product under undisclosed terms (5/16) |
Exiqon A/S* |
Roche Diagnostics (Switzerland) |
Roche was named sole distributor of Exiqon's ProbeLibrary Kits |
The kits are used for gene expression analysis and target validation of microarray experiments; terms were not disclosed (5/17) |
InSite Vision |
Unnamed company |
They signed a deal for the long-term supply of azithromycin |
Azithromycin is the active drug in InSite's AzaSite ocular anti-infective product, which is in Phase III trials (5/18) |
Novavax Inc. |
Cardinal Health Inc. |
They restructured agreement for the manufacture of Novavax's Estrasorb |
Novavax will manufacture the topical emulsion for estrogen therapy; Cardinal will take care of fill-finish operations; the move is expected to reduce Novavax's manufacturing costs (5/9) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange. | |||
To read more on related topics, click on one of the words below.